Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin ...

Researchers at the University of Rochester have described a neuroimaging-based biomarker that could identify individuals with early psychosis, and improved their identification when it was added to a ...

HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers ...

The enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a regulator of de novo NAD+ synthesis and is reduced in ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition ...

To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a ...

The FDA announced a new pilot program for communication of medical device recalls, but industry may be wary of a program that ...

Oxford Nanopore Technologies Ltd. has established a new collaboration with UK Biobank to create the world’s first ...

Previous laboratory and clinical studies showed that inhibiting the activation of the MAPK signaling pathway could attenuate acute lung injury.

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

Empyrean Therapeutics Inc. has acquired a first-in-class TLR2 antagonist molecule from Eos Therapies Inc. with the aim of ...

The first day of the U.S. FDA’s two-day advisory hearing on generative artificial intelligence reflected some of the ...